231 publications
Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases
Zorginstituut Nederland has carried out an assessment of the medicinal product hydrocortisone sodium phosphate (Softacor®) can be ...
Room for improvement analysis: Peripheral Arterial Disease – Zinnige Zorg
This Room for Improvement Analysis describes the research and the resulting actions and agreements that focus on further ...
Roflumilast (Daxas®) for maintenance treatment of severe chronic obstructive lung disease (COPD)
Zorginstituut Nederland has carried out an assessment of whether roflumilast (Daxas®) is interchangeable with a drug currently ...
SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions
Zorginstituut Nederland has carried out a substantive assessment of whether the existing list 2 conditions for SGLT2 inhibitors ...
Teduglutide (Revestive®) for the treatment of short bowel syndrome
The Minister of Health, Welfare and Sport (VWS) has asked Zorginstituut Nederland to carry out an assessment of teduglutide ...
Obeticholic acid (Ocaliva®) for the treatment of primary biliary cholangitis
Zorginstituut Nederland carried out an assessment of whether obeticholic acid (Ocaliva®) is interchangeable with a drug currently ...
Cariprazine (Reagila®) for the treatment of schizophrenia
The Minister of Health, Welfare and Sport (WVS) asked Zorginstituut Nederland (National Health Care Institute) to carry out a ...
Dimethyl fumarate (Skilarence®) for the treatment of plaque psoriasis in adults
The Minister of Health, Welfare and Sport (WVS) asked Zorginstituut Nederland (National Health Care Institute) to carry out an ...
Flash Glucose Monitoring (FGM)
In this report Zorginstituut Nederland (National Health Care Institute) assesses whether Flash Glucose Monitoring (FGM) complies ...
Rolapitant (Varuby®) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults
Zorginstituut Nederland has carried out an assessment of the medicinal product rolapitant (Varuby®). The GVS report concludes ...